No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin

S. Wilkening, K. Hemminki, P. Rudnai, E. Gurzau, K. Koppova, A. Försti, R. Kumar

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: The MDM2 oncoprotein promotes cell survival and cell cycle progression by inhibiting the p53 tumour suppressor protein. Further, overexpression of the MDM2 gene can inhibit DNA double-strand break repair in a p53-independent manner. Recent studies have shown that a single nucleotide polymorphism (SNP) in the intronic promoter region of MDM2 (called SNP309) can significantly change the expression of MDM2 and thereby suppress the p53 pathway. This SNP was also found to be associated with the onset and risk of different cancer types. Basal cell carcinoma of the skin (BCC) is one of the most common neoplasms in the world. BCC development is associated with environmental factors (especially sun exposure) as well as heritable factors. Objectives: The present case-control study investigated the association of the MDM2 SNP309 with the risk and the age at onset of BCC. Methods: Data from 509 individuals affected by BCC and 513 healthy controls were genotyped with TaqMan polymerase chain reaction. Results Cases and controls showed a similar genotype distribution and the SNP did not modify the age at onset of BCC. Conclusions: These results suggest that the MDM2 SNP309 alone affects neither the risk nor the age at onset of BCC.

Original languageEnglish
Pages (from-to)375-377
Number of pages3
JournalBritish Journal of Dermatology
Volume157
Issue number2
DOIs
Publication statusPublished - Aug 2007

Fingerprint

Basal Cell Carcinoma
Skin
Age of Onset
Single Nucleotide Polymorphism
Tumor Suppressor Protein p53
Double-Stranded DNA Breaks
Oncogene Proteins
Solar System
Genetic Promoter Regions
Case-Control Studies
Neoplasms
Cell Survival
Cell Cycle
Genotype
Polymerase Chain Reaction
Genes

Keywords

  • Basal cell carcinoma of the skin
  • MDM2
  • Promoter
  • Single nucleotide polymorphism

ASJC Scopus subject areas

  • Dermatology

Cite this

No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin. / Wilkening, S.; Hemminki, K.; Rudnai, P.; Gurzau, E.; Koppova, K.; Försti, A.; Kumar, R.

In: British Journal of Dermatology, Vol. 157, No. 2, 08.2007, p. 375-377.

Research output: Contribution to journalArticle

Wilkening, S. ; Hemminki, K. ; Rudnai, P. ; Gurzau, E. ; Koppova, K. ; Försti, A. ; Kumar, R. / No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin. In: British Journal of Dermatology. 2007 ; Vol. 157, No. 2. pp. 375-377.
@article{5f283c5d059e46e185eb1b5ac8c3c72e,
title = "No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin",
abstract = "Background: The MDM2 oncoprotein promotes cell survival and cell cycle progression by inhibiting the p53 tumour suppressor protein. Further, overexpression of the MDM2 gene can inhibit DNA double-strand break repair in a p53-independent manner. Recent studies have shown that a single nucleotide polymorphism (SNP) in the intronic promoter region of MDM2 (called SNP309) can significantly change the expression of MDM2 and thereby suppress the p53 pathway. This SNP was also found to be associated with the onset and risk of different cancer types. Basal cell carcinoma of the skin (BCC) is one of the most common neoplasms in the world. BCC development is associated with environmental factors (especially sun exposure) as well as heritable factors. Objectives: The present case-control study investigated the association of the MDM2 SNP309 with the risk and the age at onset of BCC. Methods: Data from 509 individuals affected by BCC and 513 healthy controls were genotyped with TaqMan polymerase chain reaction. Results Cases and controls showed a similar genotype distribution and the SNP did not modify the age at onset of BCC. Conclusions: These results suggest that the MDM2 SNP309 alone affects neither the risk nor the age at onset of BCC.",
keywords = "Basal cell carcinoma of the skin, MDM2, Promoter, Single nucleotide polymorphism",
author = "S. Wilkening and K. Hemminki and P. Rudnai and E. Gurzau and K. Koppova and A. F{\"o}rsti and R. Kumar",
year = "2007",
month = "8",
doi = "10.1111/j.1365-2133.2007.07994.x",
language = "English",
volume = "157",
pages = "375--377",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin

AU - Wilkening, S.

AU - Hemminki, K.

AU - Rudnai, P.

AU - Gurzau, E.

AU - Koppova, K.

AU - Försti, A.

AU - Kumar, R.

PY - 2007/8

Y1 - 2007/8

N2 - Background: The MDM2 oncoprotein promotes cell survival and cell cycle progression by inhibiting the p53 tumour suppressor protein. Further, overexpression of the MDM2 gene can inhibit DNA double-strand break repair in a p53-independent manner. Recent studies have shown that a single nucleotide polymorphism (SNP) in the intronic promoter region of MDM2 (called SNP309) can significantly change the expression of MDM2 and thereby suppress the p53 pathway. This SNP was also found to be associated with the onset and risk of different cancer types. Basal cell carcinoma of the skin (BCC) is one of the most common neoplasms in the world. BCC development is associated with environmental factors (especially sun exposure) as well as heritable factors. Objectives: The present case-control study investigated the association of the MDM2 SNP309 with the risk and the age at onset of BCC. Methods: Data from 509 individuals affected by BCC and 513 healthy controls were genotyped with TaqMan polymerase chain reaction. Results Cases and controls showed a similar genotype distribution and the SNP did not modify the age at onset of BCC. Conclusions: These results suggest that the MDM2 SNP309 alone affects neither the risk nor the age at onset of BCC.

AB - Background: The MDM2 oncoprotein promotes cell survival and cell cycle progression by inhibiting the p53 tumour suppressor protein. Further, overexpression of the MDM2 gene can inhibit DNA double-strand break repair in a p53-independent manner. Recent studies have shown that a single nucleotide polymorphism (SNP) in the intronic promoter region of MDM2 (called SNP309) can significantly change the expression of MDM2 and thereby suppress the p53 pathway. This SNP was also found to be associated with the onset and risk of different cancer types. Basal cell carcinoma of the skin (BCC) is one of the most common neoplasms in the world. BCC development is associated with environmental factors (especially sun exposure) as well as heritable factors. Objectives: The present case-control study investigated the association of the MDM2 SNP309 with the risk and the age at onset of BCC. Methods: Data from 509 individuals affected by BCC and 513 healthy controls were genotyped with TaqMan polymerase chain reaction. Results Cases and controls showed a similar genotype distribution and the SNP did not modify the age at onset of BCC. Conclusions: These results suggest that the MDM2 SNP309 alone affects neither the risk nor the age at onset of BCC.

KW - Basal cell carcinoma of the skin

KW - MDM2

KW - Promoter

KW - Single nucleotide polymorphism

UR - http://www.scopus.com/inward/record.url?scp=34447542807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447542807&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2133.2007.07994.x

DO - 10.1111/j.1365-2133.2007.07994.x

M3 - Article

C2 - 17553029

AN - SCOPUS:34447542807

VL - 157

SP - 375

EP - 377

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 2

ER -